Publication Name	World Journal of Gastroenterology
Manuscript ID	5960
Country	Hungary

Received	2013-09-29 08:37
Peer-Review Started	2013-09-29 08:42
To Make the First Decision	2013-12-16 17:09
Return for Revision	2013-12-17 15:12
Revised	2014-01-08 21:32
Second Decision	2014-04-03 10:14
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-04-03 12:29
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-05-06 15:34
Publish the Manuscript Online	2014-05-28 11:45

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Role of antispasmodics in the treatment of irritable bowel syndrome
Manuscript Source	Invited Manuscript
All Author List	Anita Annaházi, Richárd Róka, András Rosztóczy and Tibor Wittmann
Funding Agency and Grant Number
Corresponding Author	Tibor Wittmann, MD, PhD, Professor, First Department of Medicine, University of Szeged, Korányi fasor 8-10, 6720 Szeged, Hungary. wittmann.tibor@med.u-szeged.hu
Key Words	Irritable bowel syndrome; Motility; Treatment; Calcium channel blockers; Spasmolytics
Core Tip	Treatment of irritable bowel syndrome (IBS) must target intestinal motility alterations and visceral hypersensitivity. Antispasmodics have been used in the treatment of IBS for decades, and large placebo-controlled trials have recently been conducted on their efficacy. Alverine citrate, in combination with simethicone, effectively reduced abdominal pain and discomfort; while otilonium bromide also improved defecation problems. Pinaverium bromide regulated impaired motility and reduced stool complaints. Phloroglucinol and trimethylphloroglucinol reduced pain in IBS patients. Mebeverine was recently found to be effective only in non-placebo-controlled trials. Antispasmodics are considered safe. T-type calcium channel blockers could represent a future therapeutic option in IBS treatment.
Publish Date	2014-05-28 11:45
Citation	Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol 2014; 20(20): 6031-6043
URL	http://www.wjgnet.com/1007-9327/full/v20/i20/6031.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i20.6031

Full Article (PDF)	WJG-20-6031.pdf
Full Article (Word)	WJG-20-6031.doc
Manuscript File	5960-Review.doc
Answering Reviewers	5960-Answering reviewers.pdf
Copyright License Agreement	5960-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5960-Language certificate.pdf
Peer-review Report	5960-Peer reviews.pdf
Scientific Editor Work List	5960-Scientific editor work list.doc